You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 136 No. 9, September 1982 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  ARTICLES
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Intravenous Indomethacin Therapy in Premature Infants With Patent Ductus Arteriosus

Causes of Death and One-Year Follow-up

Tsu F. Yeh, MD; Hilda R. Goldbarg, MD; Tomacine Henek, PhD; Amin Thalji, MD; Rosita S. Pildes, MD

Am J Dis Child. 1982;136(9):803-807.


Abstract



• Fifty-five infants participated in a double-blind study of indomethacin therapy for the closure of patent ductus arteriosus. Seventeen infants died. There was no significant difference in autopsy findings between the groups with respect to pneumonia, disseminated intravascular coagulopathy, necrotizing enterocolitis, sepsis, intraventricular hemorrhage, hydrocephalus, kernicterus, brain softening, and renal damage. For those infants who survived and returned for follow-up at approximately 1 year of age, there was no significant difference between the control (n = 17) and indomethacin (n = 13) groups with respect to physical growth, Bayley scores, respiratory infection, abnormal eye ground, neurological defects, and abnormal EEG. Four in the control group (24%) and three in the indomethacin group (23%) had moderate to severe neurological defects and/or scored less than 80 on the Bayley Mental Development Index or Psychomotor Development Index. It appeared that indomethacin therapy did not have a long-term adverse effect on premature infants.

(Am J Dis Child 1982;136:803-807)



Author Affiliations



From the Divisions of Neonatology (Drs Yeh, Thalji, and Pildes) and Pediatric Neurology (Dr Goldbarg), Department of Pediatric Psychiatry (Dr Henek), Cook County Hospital and the University of Illinois College of Medicine, Chicago.


Footnotes



Reprint requests to Division of Neonatology, Cook County Children's Hospital, 700 S Wood St, Chicago, IL 60612 (Dr Yeh).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Network meta-analysis of indomethacin versus ibuprofen versus placebo for PDA in preterm infants
Jones et al.
Arch. Dis. Child. Fetal Neonatal Ed. 2011;96:F45-F52.
ABSTRACT | FULL TEXT  

Developmental Sequelae in Premature Infants Undergoing Ligation of Patent Ductus Arteriosus
Wilkerson et al.
Ann. Thorac. Surg. 1985;39:541-546.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.